Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors. by Lotta, Luca et al.
1 
 
Association of genetic variants related to gluteofemoral versus abdominal fat 1 
distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors 2 
 3 
Luca A Lotta, MD, PhD,
1
 Laura BL Wittemans, MSc,
1
 Verena Zuber, PhD,
2
 Isobel D 4 
Stewart, PhD,
1
 Stephen J Sharp, MSc,
1
 Jian'an Luan, PhD,
1
 Felix R Day, PhD,
1
 Chen Li, 5 
MSc,
1
 Nicholas Bowker, MSc,
1
 Lina Cai, MSc,
1
 Emanuella De Lucia Rolfe, PhD,
1
 Kay-Tee 6 
Khaw, MB, ChB, MSc,
3
 John RB Perry, PhD,
1
 Stephen O'Rahilly, MD,
4
 Robert A Scott, 7 
PhD,
1
 David B Savage, MD,
4
 Stephen Burgess, PhD,
2,3
 Nicholas J Wareham, MBBS, PhD,
1
 8 
Claudia Langenberg, MD, PhD.
1
 9 
 10 
1 MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom 11 
2 MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom 12 
3 Department of Public Health and Primary Care, University of Cambridge, Cambridge, 13 
United Kingdom 14 
4 Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, 15 
Cambridge, United Kingdom 16 
 17 
 18 
 19 
Word Count (Abstract): 400 20 
Word Count (Text): 4,503 21 
Tables: 2 22 
Figures: 2 23 
 24 
 25 
Correspondence to: 26 
Claudia Langenberg (claudia.langenberg@mrc-epid.cam.ac.uk) 27 
Luca A Lotta (luca.lotta@mrc-epid.cam.ac.uk) 28 
MRC Epidemiology Unit 29 
University of Cambridge 30 
Cambridge  31 
CB20QQ 32 
United Kingdom 33 
Tel. +44 (0)1223 330315 34 
Fax. +44 (0)1223 330316 35 
 36 
37 
2 
 
Abstract 38 
 39 
Importance: Body fat distribution, usually measured using waist-to-hip ratio (WHR), is an important 40 
contributor to cardio-metabolic disease independent of body mass index (BMI). Whether mechanisms 41 
that increase WHR via lower gluteofemoral (hip) or via higher abdominal (waist) fat distribution 42 
affect cardio-metabolic risk is unknown. 43 
 44 
Objective: To identify genetic variants associated with higher WHR specifically via lower 45 
gluteofemoral or higher abdominal fat distribution and estimate their association with cardio-46 
metabolic risk. 47 
 48 
Design, Setting, and Participants: Genome-wide association studies (GWAS) for WHR combined 49 
data from the UK Biobank cohort and summary statistics from previous GWAS (data collection: 50 
2006-2018). Specific polygenic scores for higher WHR via lower gluteofemoral or via higher 51 
abdominal fat distribution were derived using WHR-associated genetic variants showing specific 52 
association with hip or waist circumference. Associations of polygenic scores with outcomes were 53 
estimated in three population-based cohorts, a case-cohort study and summary statistics from 6 54 
GWAS (data collection: 1991-2018). 55 
 56 
Exposures: Over 2.4 million common genetic variants (GWAS); polygenic scores for higher WHR 57 
(follow-up analyses). 58 
 59 
Main outcomes and measures: BMI-adjusted WHR and unadjusted WHR (GWAS); compartmental 60 
fat mass measured by dual-energy X-ray absorptiometry (DEXA), systolic, diastolic blood pressure, 61 
low-density lipoprotein cholesterol, triglycerides, fasting glucose, fasting insulin, type 2 diabetes and 62 
coronary disease risk (follow-up analyses). 63 
 64 
Results: Among 452,302 European-ancestry UK Biobank participants, mean age was 57 (SD=8) 65 
years and mean WHR was 0.87 (SD=0.09). In genome-wide analyses, 202 independent genetic 66 
variants were associated with higher BMI-adjusted WHR (N=660,648) and unadjusted WHR 67 
(N=663,598). In DEXA analyses (N=18,330), the hip- and waist-specific polygenic scores for higher 68 
WHR were specifically associated with lower gluteofemoral and higher abdominal fat, respectively. 69 
In follow-up analyses (N=636,607), both polygenic scores were associated with higher blood 70 
pressure, triglycerides and higher risk of diabetes (waist-specific score: odds ratio [OR], 1.57 [95% 71 
CI, 1.34-1.83], absolute risk increase per 1000 participant-years [ARI], 4.4 [95% CI, 2.7-6.5], P<.001; 72 
hip-specific score: OR, 2.54 [95% CI, 2.17-2.96], ARI, 12.0 [95% CI, 9.1-15.3], P<.001) and 73 
coronary disease (waist-specific score: OR, 1.60 [95% CI, 1.39-1.84], ARI, 2.3 [95% CI, 1.5-3.3], 74 
P<.001; hip-specific score: OR, 1.76 [95% CI, 1.53-2.02], ARI, 3.0 [95% CI, 2.1-4.0], P<.001), per 1 75 
SD increase in BMI-adjusted WHR.  76 
 77 
Conclusions and Relevance: Distinct genetic mechanisms may be linked to gluteofemoral and 78 
abdominal fat distribution that are the basis for the calculation of the waist-to-hip ratio. If replicated in 79 
additional diverse populations, these findings may have implications for risk assessment and treatment 80 
of diabetes and coronary disease.   81 
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Key points 82 
 83 
Question: Do genetic variants that are related to body fat distribution via lower levels of 84 
gluteofemoral (hip) fat or via higher levels of abdominal (waist) fat show associations with 85 
diabetes or coronary disease risk? 86 
 87 
Findings: In genetic studies including up to 636,607 people, distinct polygenic risk scores for 88 
increased waist-to-hip ratio via lower gluteofemoral or via higher abdominal fat distribution 89 
were significantly associated with higher levels of cardio-metabolic risk factors and higher 90 
risk for type 2 diabetes and coronary disease.  91 
 92 
Meaning: Genetic mechanisms specifically linked to lower gluteofemoral or higher 93 
abdominal fat distribution may independently contribute to the relationship between body 94 
shape and cardio-metabolic risk.   95 
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Introduction 96 
 The distribution of body fat is associated with the propensity of overweight individuals 97 
to manifest insulin resistance and its associated metabolic and cardiovascular complications.
1-98 
5
 The waist-to-hip ratio (WHR) is a widely-used, convenient and robustly validated indicator 99 
of fat distribution and is linked to the risk of type 2 diabetes and coronary disease 100 
independently of body mass index (BMI).
1-5
 This observation has been used to infer that 101 
accumulation of fat in the abdominal cavity is an independent causal contributor to cardio-102 
metabolic disease. Whilst many studies support this assertion and plausible mechanisms have 103 
been proposed, the waist-to-hip ratio can also be increased by a reduction in its denominator, 104 
the hip circumference. Evidence from several different forms of partial lipodystrophy
6,7
 and 105 
functional studies of peripheral adipose storage compartments
8-10
 suggests that a primary 106 
inability to expand gluteofemoral or hip fat can also underpin subsequent cardio-metabolic 107 
disease risk. Emerging evidence from the analysis of common genetic variants associated 108 
with greater insulin resistance but lower levels of hip fat suggests that similar mechanisms 109 
may also be relevant to the general population.
11-14
  110 
 In this study, large-scale human genetic data were used to investigate whether genetic 111 
variants related to body fat distribution via lower levels of gluteofemoral (hip) fat or via 112 
higher levels of abdominal (waist) fat are associated with type 2 diabetes or coronary disease 113 
risk.  114 
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Methods 115 
Study design 116 
 A multi-stage approach was adopted (Table 1). In Stage 1, genome-wide association 117 
studies (GWAS) of waist-to-hip ratio with (WHRBMI-adjusted) and without (WHRunadjusted) 118 
adjustment for BMI were performed to identify genetic variants associated with fat 119 
distribution. Stage 1 included data from European ancestry participants of the UK Biobank 120 
study and summary statistics from previously-published GWAS of the Genetic Investigation 121 
of Anthropometric Traits (GIANT) consortium.
15
 In Stage 2, general, hip- and waist-specific 122 
polygenic scores for higher WHR were derived using 202 genetic variants independently 123 
associated with WHR in Stage 1. Stage 2 included data from European ancestry participants 124 
of UK Biobank and summary statistics from GIANT.
15
 In Stage 3, associations of polygenic 125 
scores with compartmental fat mass measured by dual-energy X-ray absorptiometry (DEXA) 126 
were estimated in European ancestry participants from the UK Biobank, Fenland and EPIC-127 
Norfolk studies. In Stage 4, associations of polygenic scores with six cardio-metabolic risk 128 
factors and with risk of type 2 diabetes and coronary artery disease were estimated using data 129 
from European ancestry participants of UK Biobank, the EPIC-InterAct case-cohort study 130 
and summary statistics from 6 previously-published GWAS. All studies were approved by 131 
local institutional review boards and ethics committees and participants gave written 132 
informed consent. 133 
 134 
Studies and participants 135 
 UK Biobank (data collection: 2006-2018) is a prospective population-based cohort study 136 
of people aged 40-69 years who were recruited in 2006-2010 from 22 centers located in 137 
urban and rural areas across the United Kingdom.
16
  138 
 Fenland (data collection: 2005-2018) is a prospective population-based cohort study of 139 
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people born in 1950-1975 and recruited in 2005-2015 from outpatient primary care clinics in 140 
Cambridge, Ely and Wisbech (United Kingdom).
11
  141 
 EPIC-Norfolk (data collection: 1993-2018) is a prospective population-based cohort 142 
study of individuals aged 40-79 and living in the Norfolk county (rural areas, market towns 143 
and the city of Norwich) in the United Kingdom at recruitment from outpatient primary care 144 
clinics in 1993-1997.
17
  145 
 EPIC-InterAct (data collection: 1991-2018) is a case-cohort study nested within the 146 
European Prospective Investigation into Cancer and Nutrition (EPIC) study, a prospective 147 
cohort study.
18
 EPIC study participants who developed type 2 diabetes after study baseline 148 
constituted the incident case group of EPIC-InterAct and a randomly-selected group of 149 
individuals free of diabetes at baseline constituted the subcohort.  150 
 Summary statistics from 11 GWAS published by research consortia between 2012 and 151 
2015 were used in the different stages of the study (eMethods 1 and eTable 1). These 152 
included genetic variant associations with BMI, WHRBMI-adjusted, WHRunadjusted, waist- and 153 
hip-circumference from the GIANT consortium,
15,19
 associations with fasting glucose and 154 
fasting insulin from the Meta-analyses of Glucose and Insulin-related Traits consortium 155 
(MAGIC),
20,21
 associations with triglycerides and low-density lipoprotein cholesterol (LDL-156 
C) from the Global Lipid Genetic consortium (GLGC),
22
 associations with type 2 diabetes 157 
from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium
23
 and 158 
with coronary artery disease from the Coronary Artery Disease Genome-wide Replication 159 
and Meta-analysis plus the Coronary Artery Disease Genetics consortium 160 
(CARDIOGRAMplusC4D).
24
 Data collection took place in 2012-2016.  161 
 Detailed descriptions of study design, sources of data, and participants in each stage are 162 
in Tables 1-2, eMethods 1 and eTables 1-3. 163 
 164 
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Outcomes  165 
 Outcomes of the study were WHR (Stage 1 and 2b), hip and waist circumference (Stage 166 
2a), compartmental body fat masses (Stage 3), six cardio-metabolic risk factors (systolic and 167 
diastolic blood pressure, fasting glucose, fasting insulin, triglycerides and LDL-C; Stage 4) 168 
and two disease outcomes (type 2 diabetes and coronary disease; Stage 4).  169 
 Stage 1 and 2: WHR was defined as the ratio of the circumference of the waist to that of 170 
the hip, both of which were estimated in cm using a Seca 200-cm tape measure. BMI-171 
adjusted WHR was obtained by calculating the residuals for a linear regression model of 172 
WHR on age, sex and BMI. 173 
 Stage 3: compartmental fat masses were measured in grams by DEXA, a whole-body, 174 
low-intensity X-ray scan that precisely quantifies fat mass in different body regions. In UK 175 
Biobank, DEXA measures were obtained using a GE-Lunar iDXA instrument. In Fenland 176 
and EPIC-Norfolk, DEXA scans were performed using a Lunar Prodigy advanced fan beam 177 
scanner (GE Healthcare, Bedford, UK). Participants were scanned by trained operators using 178 
standard imaging and positioning protocols. All the images were manually processed by one 179 
trained researcher, who corrected DEXA demarcations according to a standardized procedure 180 
as illustrated in eFigure 1 and described in eMethods 1. In brief, the arm region included the 181 
arm and shoulder area, the trunk region included the neck, chest, abdominal and pelvic areas. 182 
The abdominal region was defined as the area between the ribs and the pelvis, and was 183 
enclosed by the trunk region. The leg region included all of the area below the lines that form 184 
the lower borders of the trunk. The gluteofemoral region included the hips and upper thighs, 185 
and overlapped both leg and trunk regions. The upper demarcation of this region was below 186 
the top of the iliac crest at a distance of 1.5 times the abdominal height. The DEXA 187 
CoreScan® software (GE Healthcare, Bedford UK) was used to determine visceral 188 
abdominal fat mass within the abdominal region. 189 
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 Stage 4, risk factors: systolic and diastolic blood pressures were defined as the values of 190 
arterial blood pressure in mmHg measured using an Omron monitor during the systolic and 191 
diastolic phases of the heart cycle. Fasting insulin and fasting glucose were defined as the 192 
values of insulin (log-transformed and expressed in log-pmol/L) in serum and glucose 193 
(mmol/L) in whole blood measured in fasting state in non-diabetic individuals as previously 194 
described.
20,21
 Triglycerides (log-transformed and expressed in log-mmol/L) and LDL-C 195 
(mmol/L) levels in the circulation were measured using biochemical assays (triglycerides and 196 
24% of LDL-C values in the GLGC study
22
) or derived with the Friedewald formula (76% of 197 
LDL-C values in the GLGC study
22
) as previously described.
22
  198 
 Stage 4, disease outcomes: for disease outcomes analyses in UK Biobank, binary 199 
definitions of prevalent disease status and a case-control analytical design were used in line 200 
with previous work.
11,25,26
 Definition of prevalent diabetes was consistent with validated 201 
algorithms.
25
 Participants were classified as cases of prevalent type 2 diabetes if they met the 202 
following two criteria: (1) self-reported type 2 diabetes diagnosis or self-reported diabetes 203 
medication at nurse interview or at digital questionnaire, or electronic health record 204 
consistent with type 2 diabetes (International Statistical Classification of Diseases and 205 
Related Health Problems version 10 [ICD-10] code E11); and (2) age at diagnosis >36 years 206 
or use of oral anti-diabetic medications (to remove likely type 1 diabetes cases). Controls 207 
were participants who (1) did not self-report a diagnosis of diabetes of any type, and (2) did 208 
not take any diabetes medications, and (3) did not have an electronic health record of diabetes 209 
of any type. In EPIC-InterAct, the outcome was incident type 2 diabetes. Incident type 2 210 
diabetes case status was defined on the basis of evidence of type 2 diabetes from self-report, 211 
primary care registers, drug registers (medication use), hospital record or mortality data.
18
 212 
Incident type 2 diabetes cases were considered to be verified if evidence from a minimum of 213 
two of these independent sources was present.
18
 Participants free from type 2 diabetes at 214 
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baseline were randomly selected from participating EPIC-study cohorts and constituted the 215 
subcohort group of EPIC-InterAct. Participants with prevalent diabetes at study baseline were 216 
excluded from EPIC-InterAct. In UK Biobank, prevalent coronary artery disease was defined 217 
as either (1) myocardial infarction or coronary disease documented in the participant’s 218 
medical history at the time of enrolment by a trained nurse or (2) an electronic health record 219 
of acute myocardial infarction or its complications (ICD-10 codes I21-I23). Controls were 220 
participants who did not meet any of these criteria. 221 
   222 
Statistical analysis  223 
 Stage 1: in UK Biobank, GWAS analyses were performed using BOLT-LMM,
27
 which 224 
fits linear mixed-models accounting for relatedness between individuals using a genomic 225 
kinship matrix.
27,28
 An inverse-variance weighted, fixed-effect meta-analysis of results from 226 
UK Biobank and GIANT was performed using METAL.
29
 This study focused on 2,446,094 227 
common genetic variants in autosomal chromosomes (i.e. not X or Y chromosome) with 228 
minor allele frequency ≥0.5% captured in both UK Biobank and GIANT. Restriction to 229 
European ancestry individuals, use of linear mixed-models (UK Biobank) and adjustment for 230 
genetic principal components and genomic inflation factor (GIANT) were used to minimize 231 
type I error. Quality measures of genuine genetic association signal versus possible 232 
confounding by population stratification or relatedness included the mean χ2 statistic, the 233 
linkage-disequilibrium score (LSDC) regression intercept and its attenuation ratio (eMethods 234 
2), as recommended for genetic studies of this size using linear mixed model estimates.
28
 235 
Values of LDSC-regression intercept below 1.5 and an attenuation ratio statistic (a measure 236 
of proportionality between LDSC-regression intercept and χ2 statistic calculated as: [LDSC 237 
intercept – 1] / [mean χ2 statistic – 1]) equal to or below 0.08 are consistent with optimal 238 
control of genetic confounding.
28
 Genetic variants were taken forward to Stage 2 if they were 239 
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associated with both WHRBMI-adjusted and WHRunadjusted
 
at the conventional genome-wide level 240 
of statistical significance
30
 (P<5×10
-08
 in each analysis). The use of both BMI-adjusted and 241 
unadjusted results prevented the inclusion of variants associated with higher WHR via 242 
collider bias
31
 or via a primary association with higher BMI. A forward-selection process was 243 
used to select independent genetic variants for Stage 2. At each iteration, the genetic variant 244 
with the lowest P-value for WHRBMI-adjusted was selected, while genetic variants within 245 
1,000,000 base pairs either side of that genetic variant were discarded from further iterations. 246 
The resulting list of genetic variants was further filtered on the basis of pairwise linkage 247 
disequilibrium such that the final list of independent genetic variants had no or negligible 248 
correlation (pairwise R
2
<.05). Full details about genetic analyses are in eMethods 2. 249 
 Stage 2: polygenic scores capturing genetic predisposition to higher WHR were derived 250 
by combining the 202 independent genetic variants from Stage 1 (or subsets of the 202 251 
variants as described below), weighted by their association with WHRBMI-adjusted in Stage 1. A 252 
general polygenic score for higher WHR was derived by combining all 202 genetic variants. 253 
A waist-specific polygenic score capturing genetic predisposition to higher WHR via higher 254 
abdominal fat was derived by combining 36 variants specifically associated with waist 255 
(P<.00025, a Bonferroni correction for 202 genetic variants) but not with hip circumference 256 
(P>.20, an arbitrary threshold). A hip-specific polygenic score capturing genetic 257 
predisposition to higher WHR via lower gluteofemoral fat was derived by combining 22 258 
variants specifically associated with hip (P<.00025) but not with waist circumference (P>.50, 259 
a stricter arbitrary threshold which was necessary because of residual associations with waist 260 
circumference of a polygenic score initially derived using P>.20, eMethods 3). A fourth 261 
polygenic score was derived by combining 144 genetic variants not included in the waist- or 262 
hip-specific polygenic scores.  263 
 The statistical performance of these polygenic scores was assessed by estimating the 264 
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proportion of the variance in WHRBMI-adjusted accounted for by the score (variance explained) 265 
and by the F-statistic (eMethods 4). The F-statistic is a measure of the ability of the 266 
polygenic score to predict the independent variable (WHRBMI-adjusted). Values of F-statistic 267 
above 10 have been considered to provide evidence of a statistically-robust polygenic 268 
score.
26,32
 Statistical power calculations for the association with disease outcomes were also 269 
performed (eMethods 4 and eFigure 2). 270 
 Stage 3 and 4: associations of polygenic scores with DEXA phenotypes, cardio-271 
metabolic risk factors and outcomes were estimated in each study separately and results were 272 
combined using fixed-effect inverse-variance weighted meta-analysis. In individual-level 273 
data analyses, polygenic scores were calculated for each study participant by adding the 274 
number of copies of each contributing genetic variant weighted by its association estimate in 275 
SD units of WHRBMI-adjusted per allele from Stage 1. Association of polygenic scores with 276 
outcomes were estimated using linear, logistic or Cox regression models as appropriate for 277 
outcome type and study design. Regression models were adjusted for age, sex and genetic 278 
principal components or a genomic kinship matrix to minimize genetic confounding. In UK 279 
Biobank disease outcomes analyses, prevalent disease status was defined as a binary variable 280 
and logistic regression was used to estimate the odds ratio of disease per 1 SD increase in 281 
WHRBMI-adjusted due to a given polygenic score. In EPIC-InterAct, Cox regression weighted 282 
for case-cohort design was used to estimate the hazard ratio of incident type 2 diabetes per 1 283 
SD increase in WHRBMI-adjusted due to a given polygenic score. In summary statistics analyses, 284 
estimates equivalent to those of individual-level analyses were obtained using inverse-285 
variance weighted meta-analysis of the association of each genetic variant in the polygenic 286 
score with the outcome, divided by the association of that genetic variant with WHRBMI-287 
adjusted.
33
 These analytical approaches assume normal distributions for polygenic scores and 288 
continuous outcomes. They also assume a linear relationship of the polygenic score with 289 
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continuous outcomes (linear regression), or with the log-odds of binary outcomes (logistic 290 
regression), or with the log-hazard of incident disease (Cox regression). All of these 291 
assumptions were largely met in this study (eMethods 5, eTable 4 and eFigures 3-6). Meta-292 
analyses of log-odds ratios and log-hazard ratios of disease assumed that these estimates are 293 
similar, an assumption which was shown to be reasonable in a sensitivity analysis conducted 294 
in EPIC-InterAct (eMethods 5 and eFigure 7). 295 
 In Stage 3 and 4, associations with continuous outcomes were expressed in standardized 296 
or clinical units of outcome per 1 SD increase in WHRBMI-adjusted (corresponding to 0.056 ratio 297 
units of age-, sex- and BMI-residualized WHR in UK Biobank) due to a given polygenic 298 
score (eMethods 5 and eTable 5). Associations with disease outcomes were expressed as 299 
odds ratios (OR) for outcome per 1 SD increase in WHRBMI-adjusted due to a given polygenic 300 
score. Absolute risk increases (ARI) for disease outcomes were estimated using the estimated 301 
ORs and the incidence of type 2 diabetes or coronary disease in the United States (eMethods 302 
5). The threshold of statistical significance for association with DEXA phenotypes was 303 
P<.0016 (0.05/32=0.0016, Bonferroni correction for 8 outcomes and 4 polygenic scores), that 304 
for association with cardio-metabolic risk factors was P<.0021 (0.05/24=0.0021, Bonferroni 305 
correction for 6 outcomes and 4 polygenic scores), and that for association with type 2 306 
diabetes and coronary disease was P<.0063 (0.05/8=0.0063, Bonferroni correction for 2 307 
outcomes and 4 polygenic scores). All reported P-values were from 2-tailed statistical tests. 308 
 In addition to deriving specific polygenic scores, the independent association of 309 
gluteofemoral or abdominal fat distribution with outcomes was studied using multivariable 310 
genetic association analyses adjusting for either of these two components of body fat 311 
distribution (eMethods 6 and eFigure 8). Adjusting for abdominal fat distribution measures 312 
was used as a way of estimating the residual association of the polygenic score with 313 
outcomes via gluteofemoral fat distribution, while adjusting for gluteofemoral fat distribution 314 
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measures as a way of estimating the residual association via abdominal fat distribution 315 
(eFigure 8). To obtain adjusted association estimates, multivariable weighted regression 316 
models were fitted in which the association of the 202-variant general polygenic score 317 
(exposure) with cardio-metabolic risk factors or diseases (outcomes) was estimated while 318 
adjusting for a polygenic score comprising the same 202 genetic variants but weighted for 319 
measures of abdominal fat distribution or measures of gluteofemoral fat distribution 320 
(covariates).
34
 A detailed description of these analysis methods and their assumptions is in 321 
eMethods 6 and eFigures 8-9. This method was also used to conduct a post hoc exploratory 322 
analysis of the association of the hip-specific polygenic score with cardio-metabolic disease 323 
outcomes after adjusting for visceral abdominal fat mass estimates. 324 
 Six different secondary or sensitivity analyses were conducted to estimate the association 325 
of polygenic scores with other phenotypes including high-density lipoprotein cholesterol 326 
(HDL-C), triglyceride/HDL-C ratio, height, and non-diabetic hyperglycemia, and to assess 327 
the robustness of the main analysis to associations with height, sex-specific associations, or 328 
the possibility of false positive associations in Stage 1 or Stage 2 (eMethods 7). 329 
 Statistical analyses were performed using STATA v14.2 (StataCorp, College Station, 330 
Texas 77845 USA), R v3.2.2 (The R Foundation for Statistical Computing), BOLT-LMM 331 
v2.3.2
27,28
 and METAL v2011-03-25.
29
  332 
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Results 333 
Genetic predisposition to higher WHR via lower gluteofemoral or via higher abdominal fat  334 
 Among 452,302 European ancestry participants of UK Biobank, mean age was 57 335 
(SD=8) years, women were 245,351 (54%) and mean WHR was 0.87 (SD=0.09; Table 2). In 336 
genome-wide association analyses of WHRBMI-adjusted (N=660,648, mean χ
2
=2.50, LDSC-337 
regression intercept, 1.098 [95% CI, 1.063, 1.134], attenuation ratio, 0.07 [95% CI, 0.04, 338 
0.09]) and WHRunadjusted (N=663,598, mean χ
2
=2.68, LDSC-regression intercept, 1.096 [95% 339 
CI, 1.064, 1.129], attenuation ratio, 0.06 [95% CI, 0.04, 0.08]) there was evidence of optimal 340 
control for genetic confounding (eMethods 2, eFigures 10-11). A total of 202 independent 341 
genetic variants were associated with both WHRBMI-adjusted and WHRunadjusted (P<5×10
-08
 in 342 
each analysis; eTable 6, eFigures 12-13). These 202 genetic variants were used to derive 343 
polygenic scores for higher WHR (Table 1). The 202-variant general score (variance in 344 
WHRBMI-adjusted explained by score in UK Biobank=3.4%, F-statistic=12,231), 22-variant hip-345 
specific score (variance explained=0.4%, F-statistic=1,550), 36-variant waist-specific score 346 
(variance explained=0.4%, F-statistic=1,444), and 144-variant general score (variance 347 
explained=2.6%, F-statistic=9,177) were statistically robust polygenic scores for WHRBMI-348 
adjusted (eMethods 4 and eFigure 2).  349 
 In 18,330 people with DEXA compartmental fat measures, all polygenic scores for 350 
higher WHR were associated with a higher abdominal-to-gluteofemoral fat mass ratio, a 351 
refined measure of body fat distribution, but were associated with different patterns of 352 
compartmental fat mass distribution (Figure 1, eFigures 14-15). The general 202-variant and 353 
144-variant polygenic scores were associated with higher visceral abdominal and lower 354 
gluteofemoral fat mass (Figure 1A, eFigure 15). The waist-specific polygenic score for 355 
higher WHR was associated with higher abdominal fat mass, but not with gluteofemoral or 356 
leg fat mass (Figure 1B). The hip-specific polygenic score for higher WHR was associated 357 
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with lower gluteofemoral and leg fat mass, but did not show statistically-significant 358 
associations with abdominal fat mass (Figure 1B). Participants with higher values of the hip-359 
specific polygenic score had numerically higher visceral abdominal fat mass, but the 360 
difference was not statistically significant when accounting for multiple tests (Figure 1B). 361 
 362 
Associations with cardio-metabolic risk factors and disease outcomes  363 
 In 636,607 people, the 202-variant polygenic score for higher WHR was associated with 364 
higher odds of type 2 diabetes and coronary artery disease and an unfavorable cardio-365 
metabolic risk profile (eFigure 16), consistent with previous studies of ~50 genetic 366 
variants.
15,26,35
 In secondary analyses, there were associations with lower HDL-C, higher 367 
triglyceride/HDL-C ratio and higher odds of non-diabetic hyperglycemia (eMethods 7 and 368 
eTables 7-8). Associations with cardio-metabolic disease outcomes were similar in men and 369 
women with no evidence of sex-interaction (Pinteraction for type 2 diabetes=0.19; Pinteraction for 370 
coronary artery disease=0.80; eTable 9).  371 
 Both hip-specific and waist-specific polygenic scores for higher WHR were associated 372 
with higher systolic, diastolic blood pressure and triglycerides (Figure 2A), with similar 373 
association estimates for a 1 SD increase in WHRBMI-adjusted. While the hip-specific polygenic 374 
score was associated with higher fasting insulin and higher LDL-C, the waist-specific 375 
polygenic score did not have statistically-significant associations with these traits (Figure 376 
2A). Both the hip-specific and the waist-specific polygenic scores were associated with 377 
higher odds of type 2 diabetes and coronary disease (Figure 2B), similarly in men and 378 
women (eTable 9). The hip-specific polygenic score had a statistically larger association 379 
estimate for diabetes than the waist-specific polygenic score per 1 SD increase in WHRBMI-380 
adjusted (OR, 2.54 [95% CI, 2.17-2.96] vs 1.57 [1.34-1.83]; ARI, 12.0 [95% CI, 9.1-15.3] vs 381 
4.4 [95% CI, 2.7-6.5] cases per 1000 participant-years; Pheterogeneity<.001; Figure 2B). In a 382 
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post-hoc multivariable analysis adjusting for visceral abdominal fat mass estimates, the hip-383 
specific polygenic score showed a statistically-significant association with higher odds of 384 
type 2 diabetes and coronary disease (OR for diabetes per 1 SD increase in WHRBMI-adjusted 385 
due to the hip-specific polygenic score, 2.84 [95% CI, 1.98-4.08], ARI, 14.4 [95% CI, 7.6-24] 386 
cases per 1000 participant-years, P<.001; OR for coronary disease, 1.74 [95% CI, 1.35-2.25], 387 
ARI, 2.9 [95% CI, 1.4-4.9] cases per 1000 participant-years, P<.001). The 144-variant 388 
polygenic score showed associations with risk factors and disease outcomes similar to those 389 
observed for the 202-variant general polygenic score (eFigure 15). Sensitivity analyses 390 
supported the robustness of the main analysis to sex-specific associations, associations with 391 
height, or the possibility of false positive associations in Stage 1 or Stage 2 (eMethods 7, 392 
eTables 9-11). 393 
 In multivariable analyses adjusting for hip circumference estimates, the 202-variant 394 
polygenic score had a pattern of association with compartmental fat mass, cardio-metabolic 395 
risk factors and disease outcomes which was similar to that of the waist-specific polygenic 396 
score (eFigure 8D and eFigure 17). The 202-variant polygenic score remained associated 397 
with higher risk of type 2 diabetes and coronary disease even when adjusting for hip 398 
circumference and leg fat mass in the same model (eTable 12).  399 
 In multivariable analyses adjusting for waist circumference estimates, the 202-variant 400 
polygenic score had a pattern of association with compartmental fat mass, cardio-metabolic 401 
risk factors and disease outcomes which was similar to that of the hip-specific polygenic 402 
score (eFigure 8C and eFigure 17). The 202-variant polygenic score remained associated 403 
with higher risk of type 2 diabetes and coronary disease even when adjusting for waist 404 
circumference and visceral abdominal fat mass in the same model (eTable 12).  405 
 In multivariable analyses adjusting for both waist and hip circumference estimates, the 406 
202-variant polygenic score was not associated with risk of type 2 diabetes or coronary 407 
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disease (eFigure 8B and eTable 12).   408 
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Discussion 409 
 This large study identified distinct genetic variants associated with a higher WHR via 410 
specific associations with lower gluteofemoral or higher abdominal fat distribution. Both 411 
these distinct sets of genetic variants were associated with higher levels of cardio-metabolic 412 
risk factors and a higher risk of type 2 diabetes and coronary disease. While this study 413 
supports the theory that an enhanced accumulation of fat in the abdominal cavity may be a 414 
cause of cardiovascular and metabolic disease, it also provides novel evidence of a possible 415 
independent role of the relative inability to expand the gluteofemoral fat compartment.  416 
 Previous studies of ~50 genomic regions associated with BMI-adjusted WHR
15
 have 417 
shown an association between genetic predisposition to higher WHR and higher risk of 418 
cardio-metabolic disease,
26,35
 mirroring the well-established BMI-independent association of 419 
a higher WHR with incident cardiovascular and metabolic disease in large-scale 420 
observational studies.
2,3
 While these results have been widely interpreted as supportive of the 421 
role of abdominal fat deposition in cardio-metabolic risk independent of overall adiposity, the 422 
etiologic contribution of lower levels of gluteofemoral and peripheral fat to these associations 423 
has not been considered.  424 
 The results of this study support the hypothesis that an impaired ability to preferentially 425 
deposit excess calories in the gluteofemoral fat compartment leads to higher cardio-metabolic 426 
risk in the general population. This is consistent with observations in severe forms of partial 427 
lipodystrophy
6,7
 and with the emerging evidence of a shared genetic background between 428 
extreme lipodystrophies and fat distribution in the general population.
11
 This large human 429 
genetic study adds to a growing body of evidence linking gluteofemoral and subcutaneous 430 
adipose tissue biology with a favorable metabolic profile.
8-10
 The hip-specific polygenic score 431 
for higher WHR was not significantly associated with measures of central fat in DEXA 432 
analyses and, in a post hoc analysis, its association with cardio-metabolic disease outcomes 433 
19 
 
was independent of visceral abdominal fat mass. These associations may perhaps reflect the 434 
secondary deposition within ectopic fat depots, such as liver, cardiac and skeletal muscle and 435 
pancreas, of excess calories that cannot be accommodated in gluteofemoral fat.
36,37
  436 
 It has been hypothesized that the association between fat distribution and cardio-437 
metabolic risk is due to an enhanced deposition of intra-abdominal fat generating a molecular 438 
milieu that fosters abdominal organ insulin resistance.
38
 The results of this study support a 439 
role of abdominal fat distribution, but they also suggest that impaired gluteofemoral fat 440 
distribution may contribute to the relationship between body shape and cardio-metabolic 441 
health outcomes.  442 
 443 
Limitations 444 
 This study has several limitations. First, as this is an observational study, it cannot 445 
establish causality. Second, the discovery and characterization of genetic variants was 446 
conducted in a large dataset but was limited to individuals of European ancestry. While the 447 
genetic determinants of anthropometric phenotypes may be partly shared across different 448 
ethnicities,
15,39,40
 further investigations in other populations and ethnicities will be required 449 
for a complete understanding of the genetic relationships between body shape and cardio-450 
metabolic risk. Third, this study was largely based on population-based cohorts, the 451 
participants of which are usually healthier than the general population, and used analytical 452 
approaches that deliberately minimize the influence of outliers, in this case people with 453 
extreme fat distribution. Genetic studies in people with extreme fat distribution may help 454 
broaden understanding of the genetic basis of this risk factor. Fourth, while disease case 455 
definitions were based on widely-adopted criteria, misclassification of cases/controls cannot 456 
be excluded, which would bias association estimates towards the null. Fifth, absolute risk 457 
increase estimates are based on incidence rates and odds ratios calculated in different 458 
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populations and therefore assume that these populations are similar. Sixth, P-value thresholds 459 
used to exclude associations with the other component of fat distribution for genetic variants 460 
included in waist- or hip-specific polygenic scores were arbitrarily chosen, but are more 461 
stringent than traditionally used cutoffs (e.g. P>.05) and polygenic score results were 462 
confirmed by multivariable genetic analyses which were independent of such thresholds. 463 
Seventh, this analysis focused on common genetic variants captured in both UK Biobank and 464 
GIANT and, by design, did not investigate the role of rare genetic variation or of other 465 
variants captured by dense imputation in UK Biobank. Eighth, there was a statistically-466 
significant difference in the association of hip- versus waist-specific polygenic scores with 467 
diabetes risk, with greater estimated magnitude of association for the hip-specific polygenic 468 
score. However, given that the difference in absolute risk was small, this observation does not 469 
necessarily represent a strong signal of mechanistic difference or differential clinical 470 
importance in the relationship between the gluteofemoral versus abdominal components of 471 
fat distribution and diabetes risk. 472 
 473 
Conclusions  474 
 Distinct genetic mechanisms may be linked to gluteofemoral and abdominal fat 475 
distribution that are the basis for the calculation of the waist-to-hip ratio. If replicated in 476 
additional diverse populations, these findings may have implications for risk assessment and 477 
treatment of diabetes and coronary disease.   478 
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Tables 507 
 508 
Table 1. Summary of the study design. 509 
 510 
Stage and aim 
Independent 
variables 
Outcome variables Outcome data sources Statistical significance 
Stage 1: Genetic discovery 
Identify genetic variants associated 
with fat distribution 
~2.4 million 
common genetic 
variants 
genome-wide 
BMI-adjusted WHR (N=660,648) 
and unadjusted WHR (N=663,598)  
UK Biobank; 
GIANT (summary statistics) 
P<5 x 10-08 in each analysis 
Stage 2a: Derivation of polygenic 
scores for higher WHR
a
 
Select genetic variants into polygenic 
scores for higher WHR capturing 
different components of fat distribution 
202 independent 
genetic variants 
from Stage 1 
Hip (N=664,446) and 
waist (N=683,549) circumference 
UK Biobank; 
GIANT (summary statistics) 
Hip- or waist specific WHR-
associated genetic variant: 
P<.00025 for association with 
either hip or waist and at least 
P>0.2 for association with the 
other 
Stage 2b: Polygenic score 
performance 
Assess polygenic scores performance 
using variance explained and F-statistic 
Four polygenic 
scores for higher 
WHRa 
BMI-adjusted WHR (N=350,721)b UK Biobank F-statistic >10 
Stage 3: Polygenic score validation 
Association of polygenic scores for 
higher WHR with detailed 
compartmental fat distribution measures 
Polygenic scores 
for higher WHR 
from Stage 2b 
Arm, trunk, abdominal, abdominal 
visceral, abdominal subcutaneous, 
gluteofemoral, leg fat mass and 
abdominal/gluteofemoral fat mass 
ratio measured by DEXA 
(N=18,330) 
Fenland; 
EPIC-Norfolk; 
UK Biobank 
P<.0016 
Stage 4: Cardio-metabolic risk 
association 
Association of polygenic scores for 
higher WHR with cardiovascular risk 
factors and disease outcomes 
Polygenic scores 
for higher WHR 
from Stage 2b 
Risk factors: systolic (N=451,402), 
diastolic (N=451,415) blood 
pressure; fasting insulin  
(N=108,557), fasting glucose 
(N=133,010); triglycerides 
(N=188,577), LDL-C (N=188,577) 
Outcomes: type 2 diabetes (69,677 
cases, 551,081 controls), coronary 
disease (85,358 cases, 551,249 
controls) 
Risk factors: UK Biobank; 
MAGIC (summary statistics); 
GLGC (summary statistics) 
Disease outcomes: UK Biobank; 
EPIC-InterAct; DIAGRAM 
(summary statistics); 
CARDIoGRAMplusC4D (summary 
statistics) 
P<.0021 for risk factors 
P<.0063 for disease outcomes 
Abbreviations: WHR, waist-to-hip ratio; BMI, body mass index; DEXA, dual-energy X-ray absorptiometry; LDL-C, low-density lipoprotein cholesterol. Studies 511 
participating in each stage are described in details in the Methods section, Table 2, eMethods 1 and eTables 1-3. 512 
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a The four polygenic scores included: (1) general polygenic score for higher WHR including all 202 independent genetic variants from Stage 1; (2) waist-specific 513 
polygenic score for higher WHR including 36 genetic variants associated with waist but not hip in Stage 2a; (3) hip-specific polygenic score for higher WHR 514 
including 22 genetic variants associated with hip but not waist in Stage 2a; (4) general polygenic score for higher WHR including 144 genetic variants not 515 
included in the waist-specific or hip-specific polygenic scores. 516 
b Variance explained was estimated using linear regression models in unrelated European ancestry participants of UK Biobank.16 517 
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Table 2. Participants of UK Biobank included in this study.  518 
 519 
Study UK Biobank 
Country United Kingdom 
Genotyping chip 
Affymetrix UK BILEVE and  
UK Biobank Axiom arrays 
Imputation panel Haplotype Reference Consortium r1.1 
Participants, N 452,302 
Female sex, N (%) 245,351 (54) 
Male sex, N (%) 206,951 (46) 
Age at baseline, mean years (SD) 57 (8) 
Age at baseline in women, mean years (SD) 57 (8) 
Age at baseline in men, mean years (SD) 57 (8) 
Currently smoking, N (%) 47,036 (10) 
Currently smoking in women, N (%) 21,867 (9) 
Currently smoking in men, N (%) 25,165 (12) 
BMI, mean kg/m2 (SD)a 27.4 (4.8) 
BMI in women, mean kg/m2 (SD) 27.0 (5.1) 
BMI in men, mean kg/m2 (SD) 27.9 (4.2) 
Waist-to-hip ratio, mean (SD) b 0.87 (0.09) 
Waist-to-hip ratio in women, mean (SD) 0.82 (0.07) 
Waist-to-hip ratio in men, mean (SD) 0.94 (0.07) 
Waist circumference, mean cm (SD) c 90 (13.5) 
Waist circumference in women, mean cm (SD) 85 (12.5) 
Waist circumference in men, mean cm (SD) 97 (11.4) 
Hip circumference, mean cm (SD)
 d
 103 (9.2) 
Hip circumference in women, mean cm (SD) 103 (10.3) 
Hip circumference in men, mean cm (SD) 104 (7.6) 
Systolic blood pressure, mean mmHg (SD)e 138 (19) 
Systolic blood pressure in women, mean mmHg (SD)e 135 (19) 
Systolic blood pressure in men, mean mmHg (SD)e 141 (17) 
Diastolic blood pressure, mean mmHg (SD)f 82 (10) 
Diastolic blood pressure in women, mean mmHg (SD)f 81 (10) 
Diastolic blood pressure in men, mean mmHg (SD)f 84 (10) 
a Missing in 1,594 participants (0.4%). 520 
b Missing in 883 participants (0.2%). 521 
c Missing in 790 participants (0.2%). 522 
d Missing in 838 participants (0.2%). 523 
e Missing in 863 participants (0.2%). 524 
f Missing in 850 participants (0.2%). 525 
Exact numbers of participants included in each genetic analysis are in eTable 1. 526 
Abbreviations: N, number of participants; BMI, body mass index; SD, standard deviation. 527 
  528 
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Figure legends 529 
 530 
 531 
Figure 1. Associations with compartmental fat mass of polygenic scores for higher WHR. Panel A 532 
shows associations with compartmental fat mass for the 202-variant general polygenic score for higher 533 
WHR. Associations are reported in clinical or standardized units of continuous outcome per 1 SD increase 534 
in WHRBMI-adjusted (corresponding to 0.056 ratio units of age-, sex- and BMI-residualized WHR in UK 535 
Biobank) due to the polygenic score. The statistical significance threshold for analyses reported in this 536 
panel was P<.0016. Panel B shows associations with compartmental fat mass for the waist- (orange) or 537 
hip- (dark blue) specific polygenic scores for higher WHR. Associations were estimated in up to 18,330 538 
European ancestry individuals from the UK Biobank,16 Fenland11 and EPIC-Norfolk17 studies. 539 
Associations are reported in clinical or standardized units of continuous outcome per 1 SD increase in 540 
WHRBMI-adjusted (corresponding to 0.056 ratio units of age-, sex- and BMI-residualized WHR in UK 541 
Biobank) due to the polygenic score used in a given analysis. The statistical significance threshold for 542 
analyses reported in this panel was P<.0016. Abbreviations: N, number of participants; SD, standard 543 
deviation; CI, confidence interval; WHR, waist-to-hip ratio; BMI, body mass index. 544 
 545 
 546 
Figure 2. Associations with cardio-metabolic risk factors and disease outcomes of waist- or hip-547 
specific polygenic scores for higher WHR. Panel A shows associations with cardio-metabolic risk 548 
factors for the waist- (orange) or hip- (dark blue) specific polygenic scores for higher WHR. Associations 549 
are reported in clinical or standardized units of continuous outcome per 1 SD increase in WHRBMI-adjusted 550 
(corresponding to 0.056 ratio units of age-, sex- and BMI-residualized WHR in UK Biobank) due to the 551 
polygenic score used in a given analysis. Data on blood pressure were from UK Biobank16; data on LDL-552 
C and triglycerides were from Global Lipids Genetics consortium22; data on fasting insulin and fasting 553 
glucose were from the Meta-analyses of Glucose and Insulin-related traits consortium20,21. The statistical 554 
significance threshold for analyses reported in this panel was P<.0021. Panel B shows associations with 555 
type 2 diabetes and coronary artery disease risk for the waist- (orange) or hip- (dark blue) specific 556 
polygenic scores for higher WHR. Associations are reported in odds ratio or absolute risk increase per 1 557 
SD increase in WHRBMI-adjusted (corresponding to 0.056 ratio units of age-, sex- and BMI-residualized 558 
WHR in UK Biobank) due to the polygenic score used in a given analysis. Associations with type 2 559 
diabetes were estimated in 69,677 cases and 551,081 controls from the DIAGRAM consortium23, EPIC-560 
InterAct18 and UK Biobank16. Associations with coronary artery disease were estimated in 85,358 cases 561 
and 551,249 controls from UK Biobank16 and the CARDIoGRAMplusC4D consortium24. The statistical 562 
significance threshold for analyses reported in this panel was P<.0063. Abbreviations: N, number of 563 
participants; SD, standard deviation; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; 564 
WHR, waist-to-hip ratio; BMI, body mass index; OR, odds ratio; ARI, absolute risk increase; py, 565 
participant-years of follow-up.  566 
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A 
    
0 -1 -.5 .5 1 1.1 
Beta (95% CI) in SD units 
per 1 SD increase in WHRBMI-adjusted 
Outcome N P 
Gluteofemoral fat mass, grams -755 (-878, -632) 18,325 6.3 x 10-32 -0.49 (-0.57, -0.41) 
Trunk fat mass, grams 1330 (867, 1792) 18,330 2.2 x 10-08 0.23 (0.15, 0.31) 
Subcutaneous  
Abdominal fat mass, grams -40 (-93,  13) 18,278 0.15 -0.06 (-0.14, 0.02) 
Visceral  
Abdominal fat mass, log (grams) 0.8 (0.6, 0.9) 18,267 4.4 x 10
-30 0.47 (0.39, 0.55) 
Abdominal fat mass, grams 318 (224, 412) 18,325 4.9 x 10-11 0.27 (0.19, 0.35) 
Arms fat mass, grams 0 (-69, 69) 18,330 0.95 -0.00 (-0.08, 0.08) 
Abdominal/gluteofemoral 
Fat mass ratio 0.21 (0.19, 0.22) 18,325 6.7 x 10
-126 0.99 (0.91, 1.07) 
Leg fat mass, grams -1920 (-2175, -1664) 18,329 3.2 x 10-48 -0.60 (-0.68, -0.52) 
Beta (95% CI) 
in clinical units 
Beta (95% CI) 
in SD units 
B 
    0 -1.5 -1 -.5 .5 1 1.5 
Beta (95% CI) in SD units 
per 1 SD increase in WHRBMI-adjusted 
N 
46 (-308, 416) 
3931 (2544, 5261) 
379 (226, 538) 
1.1 (0.7, 1.5) 
849 (566, 1131) 
365 (156, 573) 
-384 (-1152, 352) 
0.79 
2.4 x 10-08 
2.3 x 10-06 
1.8 x 10-08 
2.5 x 10-09 
0.00051 
0.24 (0.20, 0.29) 3.4 x 10-22 
0.31 
0.17 (0.13, 0.22) 1.1 x 10-12 
18,325 
18,330 
18,278 
18,267 
18,325 
18,330 
18,325 
18,329 
-1248 (-1603, -909) 2.5 x 10-12 18,325 
-520 (-1850, 809) 0.44 18,330 
-279 (-432, -126) 0.00033 18,278 
0.5 (0.1, 0.8) 0.013 18,267 
-35 (-306, 236) 0.80 18,325 
-217 (-408, -17) 0.033 18,330 
-2815 (-3551, -2111) 2.6 x 10-14 18,329 
Waist-specific polygenic score for higher WHR 
Hip-specific polygenic score for higher WHR 
Outcome 
Gluteofemoral fat, grams 
Trunk fat, grams 
Subcutaneous abdominal fat, grams 
Visceral abdominal fat, log (grams) 
Abdominal fat, grams 
Arms fat, grams 
Abdominal/gluteofemoral 
Fat mass ratio 
Leg fat, grams 
P Beta (95% CI) in clinical units 
Beta (95% CI) 
in SD units 
0.03 (-0.20, 0.27) 
0.68 (0.44, 0.91) 
0.57 (0.34, 0.81) 
0.68 (0.45, 0.92) 
0.72 (0.48, 0.96) 
0.42 (0.18, 0.66) 
-0.12 (-0.36, 0.11) 
1.17 (0.94, 1.41) 
0.83 (0.60, 1.05) 
-0.81 (-1.04, -0.59) 
-0.09 (-0.32, 0.14) 
-0.42 (-0.65, -0.19) 
0.29 (0.06, 0.52) 
-0.03 (-0.26, 0.20) 
-0.25 (-0.47, -0.02) 
-0.88 (-1.11, -0.66) 
Gluteofemoral fat, grams 
Trunk fat, grams 
Subcutaneous abdominal fat, grams 
Visceral abdominal fat, log (grams) 
Abdominal fat, grams 
Arms fat, grams 
Leg fat, grams 
Figure 1 
A 
-.5 0 .5 1 
Outcome N Beta (95% CI) In SD units P 
0.07 (-0.01, 0.16) 0.085 
0.08 (-0.01, 0.16) 0.068 
Fasting glucose,  
mmol/L 133,010 
0.16 (0.05, 0.26) 0.0035 
0.30 (0.20, 0.40) 6.5 x 10-09 
Fasting insulin, 
log (pmol/L) 108,557 
0.16 (0.11, 0.20) 1.3 x 10-11 
0.10 (0.06, 0.15) 5.5 x 10-06 
0.15 (0.11, 0.20) 2.4 x 10-11 
0.14 (0.10, 0.19) 2.1 x 10-10 
Systolic blood  
pressure, mmHg 451,402 
-0.03 (-0.13, 0.07) 0.52 
0.30 (0.21, 0.40) 9.3 x 10-10 
LDL-C, mmol/L 188,577 
0.37 (0.28, 0.46) 8.9 x 10-16 
0.46 (0.37, 0.55) 7.0 x 10-25 
Triglycerides,  
log (mmol/L) 188,577 
451,415 Diastolic blood  Pressure, mmHg 
Pheterogeneity  
in association estimates,  
waist- vs hip-specific  
polygenic score 
0.054 
0.97 
0.14 
1.9 x 10-06 
0.085 
0.68 
Waist-specific polygenic score for higher WHR 
Hip-specific polygenic score for higher WHR 
Beta (95% CI) in SD units 
per 1 SD increase in WHRBMI-adjusted 
Beta (95% CI) 
In clinical units 
0.05 (-0.01, 0.11) 
0.05 (-0.01, 0.11) 
0.10 (0.03, 0.15) 
0.18 (0.12, 0.24) 
2 (1, 2) 
1 (1, 2) 
3 (2, 4) 
3 (2, 4) 
0.0 (-0.1, 0.1) 
0.3 (0.2, 0.4) 
0.21 (0.16, 0.26) 
0.26 (0.21, 0.31) 
B 
1 1.5 2 
Outcome Cases OR (95% CI) Controls 
1.60 (1.39, 1.84) 1.1 x 10-10 
2.54 (2.17, 2.96) 1.7 x 10-32 
1.76 (1.53, 2.02) 1.3 x 10-15 
551,249 85,358 Coronary artery  
disease 
1.57 (1.34, 1.83) 1.3 x 10-08 
551,081 69,677 Type 2 diabetes 1.7 x 10-05 
0.36 
3 
Waist-specific polygenic score for higher WHR 
Hip-specific polygenic score for higher WHR 
OR (95% CI) for outcome 
per 1 SD increase in WHRBMI-adjusted 
P 
Pheterogeneity  
in association estimates,  
waist- vs hip-specific  
polygenic score 
ARI (95% CI),  
cases/1000 py 
2.3 (1.5,  3.3) 
12.0 (9.1, 15.3) 
3.0 (2.1,  4.0) 
4.4 (2.7,  6.5) 
Figure 2 
